Northeastern University FDA and eCTD Memorandum

User Generated

zzcc

Health Medical

Northeastern University

Description


Demonstrate understanding of the history and impacts of the ICH’s development of eCTD

Describe the founding regions of the ICH as well as the makeup of the ICH membership with respect to agencies and observers

  • Demonstrate knowledge of the basic structure of the eCTD
  • Demonstrate an understanding of the basic aspects of the role of regulatory affairs in the eCTD submission process
  • For this assignment, you are a Sr Manager of Regulatory Affairs at a small, emerging biotechnology company called Silencia Therapeutics.  Your company has recently successfully developed a new drug and now, you and your cross-functional colleagues at Silencia Therapeutics are planning to submit your company’s first New Drug Application (NDA) to the FDA and a Marketing Suthorization Application (MAA) to the EMA. 
  • Silencia is a small company of only 15 employees and you are the only regulatory affairs professional in its employ.  As Silencia is a small company, most of its employees do not know what ICH or the eCTD are and require some help from their regulatory affairs team members!

As the Sr Manager of Regulatory Affairs, it is your task to develop an Executive Brief that you will deliver to your peers and also the Chief officers (including CEO!) of the company.  Your executive brief needs to be 5 – 7 pages and needs to include, at a minimum, a review of the following information:

An introduction to ICH, its history, and its current membership. What countries formed the ICH?  Are regulators and industry professionals able to join?

An overview of the basics of electronic CTD. What is the eCTD and why has ICH developed this dossier format? What are the major differences between eCTD submissions to the FDA vs. EMA?

A review of the benefits of eCTD. How does eCTD help to improve the drug development process? 

Unformatted Attachment Preview

RGA6207 Fall 2021 Written Assignment #1 Executive Brief Template Prepared for the attention of: • • • • • [for example:] Chief Executive Officer, Sliencia Therapeutics Chief Scientific Officer, Silencia Therapeutics Chief Medical Officer, Silencia Therapeutics Director, Clinical Operations Medical Writing Consultant Prepared by: • [YOUR NAME], Sr Manager, Regulatory Affairs Section 1. Statement of Purpose: Use this section to describe the purpose of your executive brief, the intended audience, and what you hope to achieve by developing this executive brief. SECTION 1. Introduction to ICH: [USE THIS SECTION TO DESCRIBE THE ICH TO YOUR COLLEAGUES. INCLUDE THE HISTORY AND CURRENT MEMBERSHIP OF THE ORGANIZATION. BE SURE TO POINT OUT WHY YOU ARE TALKING ABOUT ICH (WHY IS IT RELEVANT TO ECTD?] SECTION 2. Introduction to the eCTD: [USE THIS SECTION TO DESCRIBE THE ELECTRONIC COMMON TECHNICAL DOCUMENT TO YOUR COLLEAGUES. START WITH A RATIONALE FOR WHY ICH CREATED THE ECTD AND WHY VARIOUS REGUALTORY AGENCIES, SUCH AS FDA, HAVE SINCE ADOPTED THE ECTD. CONSIDER INCLUDING THE FOLLOWING POINTS: • • • • • WHAT IS THE OVERALL STRUCTURE OF THE ECTD? WHEN IS IT USED? WHAT OTHER COUNTRIES ACCEPT ECTD FORMAT? WHAT INFORMATION IS INCLUDED IN EACH MODULE? HOW IS ECTD SUBMITTED?] SECTION 3. Benefits of eCTD: [USE THIS SECTION TO DESCRIBE THE BENEFITS OF ECTD WHICH WE HAVE DISCUSSED IN WEEKS 1 AND 2. FOR EXAMPLE, ECTD HARMOZIES THE DRUG DEVELOPMENT INFORMATION SO THAT COMPANIES ALL OVER THE WORLD CAN USE THE SAME FORMAT WHEN SUBMITTING NEW DRUG APPLICATIONS. BE THOUGHTFUL AND DO NOT JUST REPEAT WHAT IS DISCUSSED ONLINE. THINK ABOUT BRINGING IN PIECES FROM OUR CLASS DISCUSSIONS.] SECTION 4. Guidance documents and resources: RGA6207 Fall 2021 Written Assignment #1 Executive Brief Template [USE THIS SECTION TO LIST AND DESCRIBE TO YOUR COLLEAGUES THE VARIOUS GUIDANCES AND OTHER RESOURCES YOU PLAN TO USE TO HELP AID IN YOUR IND SUBMISSION (SEE THE CANVAS CORE DOCUMENTS FOR OUR CLASS AS A PLACE TO START)] References: [USE THIS SECTION FOR ALL CITATIONS]
Purchase answer to see full attachment
Explanation & Answer:
5 pages
User generated content is uploaded by users for the purposes of learning and should be used following Studypool's honor code & terms of service.

Explanation & Answer

Please view explanation and answer below.Hey! I just finished your assignment and it is attached below! 😎 If you have any other questions for me at all, please let me know and I will get back to you ASAP! 👍If everything looks great, please proceed with payment. Generous tips from students are always appreciated by tutors here at Studypool! Thank you so much!

FDA AND ECTD WRITING ASSIGNMENT

FDA and eCTD Writing Assignment #1

[Student Name]
[University/Institution]
[Course Title]
[Date Submitted]

1

FDA AND ECTD WRITING ASSIGNMENT

2

Prepared for the attention of:


Chief Officers of Silencia Therapeutics



Regulatory Affairs Department Employees

Prepared by:
1. [YOUR NAME], Sr Manager, Regulatory Affairs

Statement of Purpose:
The main objective of developing the report is to provide a detailed description of the
International Council for Harmonisation (ICH) and how to relate it to eCTD to determine how it
will affect the daily operation of Silencia Therapeutics, especially when it comes to the
development and evaluation of new drugs. By the end of the brief, everyone should have new
insights into the way the two institutions will shape the way we will develop the New Drug
Application (NDA) to the FDA and a Marketing Authorization Application (MAA) to the EMA
to ensure that the new drugs are approved and that a set foundation of organization growth and
development is established.

SECTION 1. Introduction to ICH:
The International Council for Harmonization of Technical Requirements for Pharmaceuticals for
Human Use, abbreviated as ICH, was first pioneered by the E.C., in Europe in the 1980s. The
objective of developing it was to develop a single market for pharmaceutical products. After
successfully implementing the organization in Europe, more serious discussions between Europe,
the U.S., and Japan emerged to harmonize the pharmaceutical industry. A significant step
towards achieving this was done in 1989 at the WHO Conference of Drug Regulatory

FDA AND ECTD WRITING ASSIGNMENT

3

Authorities (ICDRA) in Paris. The birth of ICH finally happened in 1990 after authorities
approached the International Federation of Pharmaceutical Manufacturers and Associations
(IFPMA) in Brussels. Afterward, Japan (MHLW/PMDA), U.S (FDA), and Europe (E.C.)
Representatives of the regulatory agencies and industry associations met to plan an International
Conference. They later met and developed Terms of Reference and decided the three criteria of
harmonization, Safety, Quality, and Efficacy that would be used for approving and authorizing
new products.

Since then, the organization has evolved immensely. A significant modification in the
organization happened on October 23 in 2015 when they held the Inaugural Assembly meeting.
The modifications included having increased international outreach, providing more in...


Anonymous
Really great stuff, couldn't ask for more.

Studypool
4.7
Trustpilot
4.5
Sitejabber
4.4

Similar Content

Related Tags